Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates

Big-selling drugs often spark legal issues as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZeneca’s potential breast cancer blockbuster is no exception.